AU2020321354A1 - Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells - Google Patents

Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells Download PDF

Info

Publication number
AU2020321354A1
AU2020321354A1 AU2020321354A AU2020321354A AU2020321354A1 AU 2020321354 A1 AU2020321354 A1 AU 2020321354A1 AU 2020321354 A AU2020321354 A AU 2020321354A AU 2020321354 A AU2020321354 A AU 2020321354A AU 2020321354 A1 AU2020321354 A1 AU 2020321354A1
Authority
AU
Australia
Prior art keywords
cells
soluble
concentration
stimulatory agent
time point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020321354A
Other languages
English (en)
Inventor
Ivan Chan
Alexandra Leida Liana LAZETIC
James Barnaby Trager
Anmol VOHRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nkarta Inc
Original Assignee
Nkarta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc filed Critical Nkarta Inc
Publication of AU2020321354A1 publication Critical patent/AU2020321354A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020321354A 2019-07-31 2020-07-29 Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells Pending AU2020321354A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962881311P 2019-07-31 2019-07-31
US62/881,311 2019-07-31
US201962932342P 2019-11-07 2019-11-07
US62/932,342 2019-11-07
PCT/US2020/044033 WO2021021907A1 (en) 2019-07-31 2020-07-29 Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells

Publications (1)

Publication Number Publication Date
AU2020321354A1 true AU2020321354A1 (en) 2022-03-03

Family

ID=74229259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020321354A Pending AU2020321354A1 (en) 2019-07-31 2020-07-29 Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells

Country Status (10)

Country Link
US (1) US20220411754A1 (https=)
EP (1) EP4003379A4 (https=)
JP (1) JP7724765B2 (https=)
KR (1) KR20220038439A (https=)
CN (1) CN114450015A (https=)
AU (1) AU2020321354A1 (https=)
CA (1) CA3144724A1 (https=)
IL (1) IL289902A (https=)
MX (1) MX2022001255A (https=)
WO (1) WO2021021907A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
CN116568805A (zh) * 2020-09-02 2023-08-08 恩卡尔塔公司 工程化自然杀伤细胞的增强扩增和细胞毒性及其用途
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
US20250339528A1 (en) * 2021-07-28 2025-11-06 Nkarta, Inc. Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cells
CN116236461B (zh) * 2021-12-08 2026-03-24 深圳先进技术研究院 一种氧化还原型纳米颗粒和活细胞载体及其应用
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
EP4649139A1 (en) * 2023-02-01 2025-11-19 Nkarta, Inc. Methods for expanding immune cells and related compositions and uses thereof
WO2025150751A1 (ko) * 2024-01-11 2025-07-17 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭용 배양보조세포 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101684456A (zh) * 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
AU2015259877B2 (en) * 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
EP3223856B1 (en) * 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP3452580B1 (en) * 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
MX2019011570A (es) * 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.

Also Published As

Publication number Publication date
EP4003379A4 (en) 2023-08-30
CN114450015A (zh) 2022-05-06
WO2021021907A1 (en) 2021-02-04
JP7724765B2 (ja) 2025-08-18
CA3144724A1 (en) 2021-02-04
JP2022542399A (ja) 2022-10-03
IL289902A (en) 2022-03-01
KR20220038439A (ko) 2022-03-28
MX2022001255A (es) 2022-05-10
US20220411754A1 (en) 2022-12-29
EP4003379A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2020321354A1 (en) Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
US20230265390A1 (en) Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof
EP3641768B1 (en) Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
US20240016840A1 (en) Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
EP3205720B1 (en) Car expression vector and car-expressing t cells
US20200024342A9 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
CN110494558B (zh) Gamma delta t细胞和增强其杀肿瘤活性的方法
CN111511911B (zh) 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
US20220211757A1 (en) Engineered gamma delta t cells and methods of making and using thereof
JP2022542321A (ja) 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
JP7820774B2 (ja) γδ型Ｔ細胞への遺伝子導入方法
RU2839702C2 (ru) Способы и композиции для усиления размножения и цитотоксичности клеток, являющихся натуральными киллерами
US20250339528A1 (en) Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cells
WO2025022372A1 (ja) 細胞集団の製造方法
TW202608911A (zh) 細胞集團之製造方法
WO2025096603A1 (en) Targeted chimeric antigen receptor modified t cells for treatment of il13ralpha2 positive malignancies